Depression affects nearly 21 million Americans annually, and for about a third of them, standard antidepressants don't work. That's where ketamine IV therapy comes in—and unlike the hype around many IV treatments, this one actually has FDA backing and published clinical evidence to support it. In 2019, the FDA approved esketamine (a ketamine derivative) as a nasal spray for treatment-resistant depression, and IV ketamine clinics have proliferated across the country since then. But the gap between what the research shows and what clinics are promising is worth examining. We're breaking down what ketamine IV therapy actually does, who it might help, and the hard truths about cost, access, and what happens after your infusion ends.
How Ketamine IV Therapy Works (The Neuroscience Behind the Hype)
Ketamine works completely differently than traditional antidepressants. SSRIs (like sertraline and fluoxetine) increase serotonin availability over weeks or months. Ketamine, by contrast, is a dissociative anesthetic that blocks NMDA receptors—and that mechanism appears to trigger rapid neuroplasticity and synapse formation within hours. Multiple studies published in JAMA Psychiatry and the Journal of Clinical Psychiatry show that ketamine can produce significant mood improvements in 24-72 hours, which is genuinely different from the 2-4 week timeline of traditional antidepressants. The effect appears to work through increased glutamate release and activation of downstream signaling pathways (particularly the mTOR pathway) that promote new neural connections. Some evidence also suggests ketamine increases brain-derived neurotrophic factor (BDNF), a protein crucial for neuroplasticity. The dissociative effects—feeling disconnected or "in another space"—are typically temporary and part of how the drug works, though clinics manage dosing to keep patients comfortable during infusions.
The Clinical Evidence: What Actually Works (and for Whom)
Here's where we need to be honest: the evidence for ketamine IV therapy is real but narrower than the marketing suggests. The strongest data supports its use for treatment-resistant depression (TRD)—specifically, depression that hasn't responded to at least two antidepressant medications. Multiple randomized controlled trials show that 50-70% of people with TRD experience significant symptom reduction after IV ketamine infusions. A landmark 2016 study in JAMA Psychiatry found that 64% of TRD patients had a response to IV ketamine versus 28% on placebo. However—and this matters—most studies are relatively short-term (weeks to a few months), and the durability of effects varies significantly. Some people maintain improvement for weeks; others relapse within days or weeks without ongoing maintenance infusions. The evidence for ketamine in treatment-resistant bipolar depression and suicidal ideation is promising but less robust. For regular depression that hasn't been treatment-resistant, the data is much thinner. Reddit threads from r/depression and r/mentalhealth consistently show mixed experiences: some users report life-changing rapid improvements, while others describe short-lived effects or disappointing results.
What to Expect During and After Ketamine IV Infusions
A typical ketamine IV protocol involves 6 infusions over 2-3 weeks (usually 40 minutes each at doses around 1-2 mg/kg), though clinics vary. During the infusion, you'll experience dissociative effects—some people describe it as dreamy, spacey, or disconnected from their body; others find it mildly uncomfortable or disorienting. Most clinics monitor your vitals and have a clinician present. You'll need someone to drive you home (you can't operate a vehicle the same day). The actual mood-boosting effects often emerge within 24 hours and can deepen over the first week. Real people on Reddit report feeling "lighter," noticing intrusive thoughts quieting down, or having energy to do things depression made impossible. However, mood effects aren't always immediate or dramatic—some describe subtle shifts rather than a switch flipping. After the initial infusion series, clinics typically recommend maintenance infusions (ranging from weekly to monthly) to sustain benefits, though insurance rarely covers these. This is crucial: ketamine IV therapy isn't a permanent cure for most people—it's more like a reset that requires ongoing treatment.
Safety, Side Effects & Who Shouldn't Get Ketamine IV
Ketamine IV is generally well-tolerated, with the most common side effects being temporary dissociation during infusions and potential mild blood pressure increases. However, ketamine isn't safe for everyone. People with active substance use disorders, psychotic disorders, or uncontrolled high blood pressure should avoid it (or require careful screening). There's also a theoretical concern about ketamine abuse potential—historically, it's been a drug of misuse—though clinical-grade IV protocols at monitored clinics carry minimal addiction risk. Longer-term safety data is still emerging; some animal studies suggest potential neurotoxicity with chronic high-dose exposure, but clinical doses appear safer. Pregnant or breastfeeding individuals should avoid it. Most importantly: ketamine IV therapy should complement, not replace, ongoing psychiatric care and psychotherapy. The research strongly suggests that ketamine works best when combined with therapy—the infusions seem to open a window for neuroplasticity, but therapy helps consolidate new thought patterns. Some clinics offer integrated care; others don't. That's a red flag worth noting when choosing a provider.
The Cost & Access Reality (And Why Insurance Rarely Covers It)
Here's the practical barrier: ketamine IV therapy is expensive. An initial series of 6 infusions typically costs $3,000-$8,000 out of pocket (sometimes higher in major cities). Maintenance infusions run $400-$1,500 per month depending on frequency. Most insurance companies—including Medicare—don't cover IV ketamine for depression, despite FDA approval of esketamine nasal spray (which some plans do cover). This is partly because esketamine is the approved form, partly due to cost-containment, and partly because the evidence base, while solid, is still being expanded. Out-of-pocket costs mean ketamine IV therapy is realistically accessible only to people with significant disposable income, creating a serious equity problem. Some clinics offer sliding scale fees or payment plans, but these are exceptions. If cost is a barrier, esketamine nasal spray (Spravato) is worth exploring—it's covered by some insurance plans and shows similar efficacy for TRD, though onset is slightly slower than IV. Clinical trials are another free option if you qualify and have access to research institutions.
Is Ketamine IV Therapy Right for You? The Honest Assessment
Ketamine IV therapy makes the most sense if: (1) you have genuine treatment-resistant depression (failed at least 2 antidepressants at adequate doses), (2) you can afford ongoing treatment (initial series + maintenance), (3) you're actively engaged in therapy or willing to start, and (4) you don't have contraindications like active substance use or psychotic disorder. It's less compelling if your depression is mild, if you haven't exhausted standard treatments, or if you're hoping for a permanent one-time cure. The research doesn't support ketamine as a first-line treatment for regular depression—standard antidepressants remain the evidence-based starting point, even if slower-acting. Real-world outcomes matter too: community reports (Reddit, patient forums) show that success is highly individual. Some people get months of improvement from one series; others need infusions every 2-4 weeks indefinitely. Both outcomes are real. Your best move: work with a psychiatrist to determine if you genuinely have TRD, then ask potential ketamine clinics about their protocol, success rates, and integration with ongoing therapy. Red flags include clinics that promise permanent cures, don't require psychiatric oversight, or don't integrate psychotherapy.
The Bottom Line
Ketamine IV therapy is one of the few IV treatments we cover that has solid clinical evidence backing it—it genuinely works for treatment-resistant depression in about half to two-thirds of people who try it, with effects that emerge in days instead of weeks. But it's not magic, it's not permanent for most people, and it's expensive. If you're treatment-resistant and can access and afford it, it's worth serious consideration alongside a psychiatrist. If you're hoping to avoid therapy, side-stepping antidepressants, or looking for a quick fix, it's not the answer. The honest take: ketamine IV therapy represents real progress for people depression has failed—but only if you approach it realistically, with ongoing psychiatric care and realistic expectations about maintenance. Start there.